Search clinical trials for: CKD732

Total 19 results

Zafgen, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers

Obesity

Australia
Zafgen, Inc.

Completed

Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers

Obesity

Australia
Zafgen, Inc.

Completed

ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Obesity

Australia
Zafgen, Inc.

Terminated

An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

Obesity | Type 2 Diabetes

Australia
Zafgen, Inc.

Completed

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury

Obesity | Craniopharyngioma | Over-weight | Hypothalamic Injury

United States, Australia
Shanghai Henlius Biotech

Withdrawn

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Advanced Solid Tumor

United States
Zafgen, Inc.

Terminated

Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome (bestPWS)

Obesity | Prader-Willi Syndrome

United States
Zafgen, Inc.

Completed

An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects

Obesity

Australia
University of Pittsburgh
ALZA

Completed

Safety Study of S-CKD602 in Patients With Advanced Malignancies

Cancer

United States
Biotheus Inc.

Recruiting

A Study of PM1015 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Zafgen, Inc.

Completed

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

Obesity | Prader-Willi Syndrome | Over-weight

United States
Shanghai Huaota Biopharmaceutical Co., Ltd.
M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Gabrail Cancer Center...

Recruiting

A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Huabo Biopharm Co., Ltd.
M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Gabrail Cancer Center...

Not yet recruiting

A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Jacobio Pharmaceuticals Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Solid Tumor

China
Bruno Bockorny
Dana-Farber Cancer Institute; Agenus Inc.

Not yet recruiting

AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

Recurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated Liposarcoma

United States
M.D. Anderson Cancer Center

Recruiting

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States
Jonsson Comprehensive Cancer Center
Arcus Biosciences, Inc.

Suspended

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States

Search clinical trials for: CKD732

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations